STOCK TITAN

Erasca (ERAS) SEC Filings, Apr-Jun 2026

ERAS NASDAQ

Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.

Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.

Rhea-AI Summary

Erasca, Inc. (ERAS) reports that Erasca Foundation proposed to sell 8,333 common shares, with an aggregate market value of $117,476.95 and an approximate sale date of June 15, 2026. Merrill Lynch is listed as the broker. The notice gives January 10, 2024 as the date of adoption of the Rule 10b5-1 plan.

The Foundation reported selling 8,333 shares on March 16, April 15 and May 15, 2026. Gross proceeds for those sales were $116,855.46, $150,843.19 and $84,528.29, respectively. David Chacko signed the notice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.28%
Tags
other
-
Rhea-AI Summary

Erasca, Inc. has a proposed sale notice for Erasca Foundation, identified as the seller and as having a foundation relationship to the issuer. The notice lists 8,333 common shares, an aggregate market value of $84,528.29, and an approximate sale date of May 15, 2026. Merrill Lynch is listed as broker, and the notice lists a Rule 10b5-1 plan adoption date of January 10, 2024. It also reports three earlier Foundation sales: 8,333 shares on February 17, 2026, for gross proceeds of $99,245.03; 8,333 shares on March 16, 2026, for $116,855.46; and 8,333 shares on April 15, 2026, for $150,843.19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
other
-
Rhea-AI Summary

Erasca, Inc. group files an amendment reporting beneficial ownership positions as of March 31, 2026. The Reporting Persons — a Venrock healthcare group and two named individuals — indicate beneficial ownership of 16,382,812 shares, representing 5.3% of Erasca's common stock based on 310,806,888 shares outstanding as of March 31, 2026. The filing breaks the position into 2,676,745 shares held by VHCP III, 267,632 shares held by VHCP Co-Investment III, and 13,438,435 shares held by VHCP EG. The report states shared voting and dispositive power for these holdings and incorporates related cover-page figures by reference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
ownership
Rhea-AI Summary

Paradigm BioCapital and related reporting persons disclosed beneficial ownership positions in Erasca, Inc. common stock. Paradigm BioCapital Advisors LP/GP and Senai Asefaw report 10,392,702 shares (representing 3.3% of the class) as of the close of business on March 31, 2026. The filing shows Paradigm BioCapital International Fund Ltd. directly owns 9,157,687 shares (2.9%).

The percentages use a share base of 310,806,888 shares outstanding as of March 31, 2026, cited from the issuer's Form 10-Q filed May 11, 2026. Reporting persons disclaim ownership except for the shares they directly beneficially own; the Adviser is identified as investment manager of the Fund and related accounts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
ownership
-
Rhea-AI Summary

T. Rowe Price Investment Management reports beneficial ownership in ERASCA INC. As of 03/31/2026 the filing shows 21,224,264 shares beneficially owned, representing 6.8% of the class. The filer discloses sole voting power over 20,502,610 shares and sole dispositive power over 21,224,264 shares.

The filing is an amendment to a Schedule 13G/A and includes a signed affirmation dated 05/15/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
ownership
-
Rhea-AI Summary

Erasca, Inc. Schedule 13G: RTW Investments, LP and Roderick Wong report shared beneficial ownership of 16,157,175 shares of Erasca common stock, representing 5.2% of the class based on 310,799,547 shares outstanding as of March 5, 2026. The filing shows shared voting and dispositive power over these shares held by the RTW Funds. The statement is signed by Dr. Wong on May 15, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
ownership
Rhea-AI Summary

Erasca, Inc. Schedule 13G/A amendment discloses institutional beneficial ownership positions held by advisory clients of Suvretta Capital Management, LLC and related parties. Suvretta reports 3,434,967 shares (1.1%) held with shared voting and dispositive power; Averill Master Fund, Ltd. reports 2,945,497 shares (0.9%).

The filing states all reported securities are directly owned by Suvretta advisory clients and that none of those clients is separately deemed to beneficially own more than 5% of the class. Shared voting and shared dispositive power are asserted for the listed holders; sole voting and sole dispositive power are reported as zero.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
ownership
-
Rhea-AI Summary

Erasca, Inc. reported first‑quarter 2026 results marked by a much larger net loss as it doubled down on its RAS/MAPK cancer franchise. Net loss widened to $183.4 million, or $0.60 per share, from $31.0 million a year earlier, mainly due to recording $150.0 million of in‑process research and development expense for expanding territorial rights under its Joyo pan‑RAS license.

Research and development spending excluding that item was $27.3 million, with $13.8 million for ERAS‑0015 and $6.7 million for ERAS‑4001, while general and administrative expense was $10.6 million. A January 2026 underwritten equity offering generated net proceeds of $242.7 million, helping lift total cash, cash equivalents, and marketable securities to $408.5 million and total assets to $461.2 million. The company now expects this liquidity to fund operations into the second half of 2028.

Erasca continues to advance ERAS‑0015 and ERAS‑4001 through early‑stage trials and has stopped development of naporafenib, terminating its Novartis license effective June 3, 2026. Management reiterates that product revenue is not expected for several years, and future funding will likely continue to rely on capital markets and partnering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
quarterly report
-
Rhea-AI Summary

Erasca reported first quarter 2026 results highlighting major investment in its RAS-targeting pipeline. The company ended March 31, 2026 with $408.5 million in cash, cash equivalents, and marketable securities and expects this to fund operations into the second half of 2028.

Total operating expenses rose to $187.9 million, driven by $150.0 million of in-process R&D expense to obtain worldwide rights to ERAS-0015, alongside $27.3 million in R&D and $10.6 million in G&A. Net loss widened to $183.4 million, or $(0.60) per share.

Strategically, Erasca advanced ERAS-0015 and ERAS-4001, signed clinical trial collaborations with Merck and Tango Therapeutics, secured a U.S. composition of matter patent for ERAS-4001 through June 2043, expanded ERAS-0015 licensing territory, and completed an upsized public offering raising approximately $258.8 million in gross proceeds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
current report
ARS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.98%
Tags
annual report

FAQ

How many Erasca (ERAS) SEC filings are available on StockTitan?

StockTitan tracks 88 SEC filings for Erasca (ERAS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Erasca (ERAS)?

The most recent SEC filing for Erasca (ERAS) was filed on November 20, 2026.